CoVPN 5002 , Version 2.0 Page 1 of 48 
 26 May 2021  CoVPN 5002   
 
 
SARS -COV -2 PREVALENCE STUDY  
 
 
DAIDS -ES ID: [ZIP_CODE]  
 
 
A Study by [CONTACT_9311] -19 Prevention Network (CoV PN) 
 
 
 
Sponsored by:  
[CONTACT_209060] (US) National Institute of Allergy and Infectious Diseases (NIAID)  
US National Institutes of Health (NIH)  
 
 
 
Non-IND Study  
 
 
Protocol Chair:  
Jessica Justman, MD  
 
Protocol Co-Chair:  
Christ opher Amos, PhD  
 
 
 
Version 2.[ADDRESS_815036] Containment  ................................ ................................ ................................ .... 24 
8.1 Ethical Review  ................................ ................................ ................................ ..................  24 
8.2 Informed Consent  ................................ ................................ ................................ .............  25 
8.3 Risks  ................................ ................................ ................................ ................................ . 26 
8.4 Benefits  ................................ ................................ ................................ .............................  26 
CoVPN 5002 , Version 2.0  Page 3 of 48 
26 May 2021  8.5 Compensation  ................................ ................................ ................................ ...................  26 
8.6 Confidentiality  ................................ ................................ ................................ ..................  26 
8.7 Communicable Disease Reporting Requirements ................................ .............................  27 
8.8 Study Discontinuation  ................................ ................................ ................................ ....... 27 
9.1 Protocol Registration  ................................ ................................ ................................ ........  27 
9.2 Study Activation  ................................ ................................ ................................ ...............  27 
9.3 Study Coordination  ................................ ................................ ................................ ...........  27 
9.4 Study Monitoring  ................................ ................................ ................................ ..............  28 
9.5 Protocol  Compliance  ................................ ................................ ................................ .........  28 
9.6 Investigator‚Äôs Records  ................................ ................................ ................................ ...... 29 
9.7 Use of Information and Publications  ................................ ................................ ................  29 
9.8 ClinicalTrials.gov  ................................ ................................ ................................ .............  29 
 
  
CoVPN 5002 , Version 2.0  Page 4 of 48 
26 May 2021  CoVPN 5002  
 
SARS -COV -2 PREVALENCE STUDY  
 
 
PROTOCOL SIGNATURE [CONTACT_614651] -ES ID # [ADDRESS_815037] this study in compliance with [LOCATION_002] (US) Health and 
Human Service regulations (45 CFR 46); applicable US Food and Drug Administration regulations; 
standar ds of the International Conference on Harmonization Guideline for Good Clinical Practice (E6); 
Institutional Review Board/Ethics Committee determinations; all applicable in -country, state, and local 
laws and regulations; and other applicable requirements ( e.g., US National Institutes of Health, Division 
of AIDS) and institutional policies.  
 
I have read and understand the information in this protocol and will ensure that all associates, colleagues, 
and employees assisting in the conduct of the study are info rmed about the obligations incurred by [CONTACT_614627].  
 
 
__________________________________ __ 
Name [CONTACT_262338] (print name)  
  
 
 
__________________________________ __         ____________________ ___ 
Signature [CONTACT_7919] o f Record               Date (DD/MONTH/YYYY)  
  
CoVPN [ADDRESS_815038] OF ABBREVIATIONS AND ACRONYMS  
 
Ab(s)   Antibody/Antibodies  
ACTG   AIDS Clinical Trials Group  
ADA   Antidrug antibodies  
AE(s)   Adverse Event(s)  
ARDS   Acute Respi[INVESTIGATOR_614608]   ([LOCATION_002]) Center for Disease Control and Prevention  
CFR   Code of Federal Regulations  
COVID -19 Coronavirus Disease 2019  
CoVPN   COVID -19 Prevention Network  
CRMS   (NIAID ) Clinical Research Management System  
CRPMC   (NIAID ) Clinical Research Products Management Center  
CRF (s)  Case Report Form (s) 
DAIDS   Division of AIDS  
DHHS   US Department of Health and Human Services  
EUA   Emergency Use Authorization  
FDA   ([LOCATION_002]) Food and Drug Administration  
HPTN   HIV Prevent ion Trials Network  
HVTN   HIV Vaccine Trials Network  
ICF(s)  Informed consent form (s) 
ICH  International Council for Harmonisation  
IDCRC   Infectious Diseases Clinical Research Consortium  
IMPAACT  International Maternal Pediatric Adolescent AIDS Clinical Trials Group  
IoR  Investigator of Record  
IRB(s)  Institutional Review Board (s) 
LAR   Legally Authorized Representative  
LC  Laboratory Center  
LOC   Leadership and Operations Center  
mAb(s)   Monoclonal Antibody/Antibodies  
MOE   margin of error  
NIAID   ([LOCATION_002]) National Institute of Allergy and Infectious Diseases  
NIH  ([LOCATION_002]) National Institutes of Health  
OHRP   Office of Human Research Protections  
PP  per-protocol  
PRO   (DAIDS) Protocol Registration Office  
RSC   (DAIDS) Regulatory Support Cen ter 
SAE (s)  Serious Adverse Event (s) 
SAP  Statistical Analysis Plan  
SDMC   Statistical and Data Management Center  
SARS   Severe Acute Respi[INVESTIGATOR_228175] -CoV -2 Severe Acute Respi[INVESTIGATOR_7531] 2  
sIRB   single IRB  
SOE   Schedule of Events  
SSP  Study -Specific Procedures manual  
TLS  Time -location Sampling  
US  [LOCATION_002]   
CoVPN 5002 , Version 2.0  Page 6 of 48 
26 May 2021   
CoVPN 5002 
 
SARS -COV -2 PREVALENCE STUDY  
 
PROTOCOL TEAM ROSTER  
 
 
PROTOCOL CHAIR:  
Jessica Justman , MD 
ICAP at Columbia  
Mailman School of Public Health  
Departments of Epi[INVESTIGATOR_614609]  
[ADDRESS_815039], NY NY [ZIP_CODE]  
Phone:  [PHONE_12697]  
Email: [EMAIL_11665]  
 
PROTOCOL CO -CHAIR  
Christopher Amos, PhD  
Dan L Duncan Comprehensive Cancer Center  
Baylor College of Medicine  
1 Baylor Plaza  
Houston, TX [ZIP_CODE]  
Email: [EMAIL_11666]  
 
Ariane van der Straten, PhD, MPH  
HPTN Socio -Behavioral and Structural Working 
Group  Liaison  
ASTRA Consulting  
Kensington , CA  9470 8 
phone: 510 -374-9187  
email: [EMAIL_11667]   
 
Ayana Moore, PhD  
Associate Project Director, HPTN  
Leadership and Operations Center  
FHI [ADDRESS_815040]. Suite 200  
Durham NC [ZIP_CODE]  
Phone:  [PHONE_10232] ext. [ZIP_CODE]  
Email: [EMAIL_11668]  
 
Daniel Szydlo , MSc   
Statistic al Research Associate  
HPTN Statistics and Data Management Center   
Fred Hutchinson Cancer Research Center  
[ADDRESS_815041] N   
Seattle, WA [ZIP_CODE]   
Phone: [PHONE_12698]  
Email:  [EMAIL_11669]   
David Burns , MD, MPH  
Medical Officer  
NIAID/NIH  
[ADDRESS_815042], Room 8B40  
Rockville MD [ZIP_CODE], [LOCATION_003]  
Phone: 301 -435-8896  
Email: [EMAIL_11670]  
 
Deborah Donnell , PhD  
Biostatistician , HPTN Statistical and Data 
Management Center  
Fred Hutchinson Cancer Research Center  
[ADDRESS_815043]. North, M2-C118   
[PO_BOX]  
Seattle, WA [ZIP_CODE]  
Phone: 206 -667-5661  
Email: [EMAIL_5211]  
 
Domonique Reed , MPH  
Research Assistant  
Mailman School of Public Health  
Department of Epi[INVESTIGATOR_614610]  
[ADDRESS_815044], NY NY [ZIP_CODE]  
Email: [EMAIL_11671]  
 
Estelle M. Pi[INVESTIGATOR_269812] -Manning, BS, MT  
Deputy Director , HPTN Laboratory Center  
Johns Hopkins University  
Pathology Building, Room [ADDRESS_815045]  
Baltimore, MD [ZIP_CODE]  
Phone: 410 -614-6736  
Email : [EMAIL_11672]  
 
CoVPN [ADDRESS_815046]. North, M2-C200   
Seattle, WA [ZIP_CODE]  
Phone:  [PHONE_2443]  
Email: [EMAIL_2099]  
 
James Kublin , MD , MPH  
Executive Director , HVTN  
Fred Hutchinson Cancer Research Center  
[ADDRESS_815047]. North, E3-300 
Seattle, WA [ZIP_CODE]  
Phone:  [PHONE_8313]  
Email: [EMAIL_7679]  
 
Jeffrey Shaman , PhD  
Mathematical Modeler  
Mailm an School of Public Health  
Department of Environmental Health Sciences 
Columbia University  
[ADDRESS_815048],  
[LOCATION_001] , NY [ZIP_CODE]  
Phone:  [PHONE_12699]  
Email: [EMAIL_11673]  
 
Jonathan Lucas, MPH  
Community Program Manager  
HPTN Leadership and Operation Center  
FHI [ADDRESS_815049]  
Durham, NC [ZIP_CODE]  
Phone : 919 -544-7040 ext. [ZIP_CODE]  
Email: [EMAIL_11023]   
 
Jontraye Davis, MHA, PMD Pro  
Community Program Manager  
HPTN Leadership and Operation Center  
FHI [ADDRESS_815050]  
Durham, NC [ZIP_CODE]  
Phone: [PHONE_10232] ext. [ZIP_CODE]  
Email: [EMAIL_11674]  
 Kathleen  Neuzil , MD, MPH, FIDSA  
Co-Principal Investigators , IDCRC  
University of Maryland School of Medicine  
[ADDRESS_815051]  
Baltimore MD [ZIP_CODE]  
Phone:  [PHONE_12700]  
Email: [EMAIL_11675]  
 
Krista Yuhas, MSc  
Statistical Research Associate  
HPTN Statistics and Data Management Center   
Fred Hutchinson Cancer Research Center  
[ADDRESS_815052] N   
Seattle, WA [ZIP_CODE]   
Phone: [PHONE_12701]  
Email:  [EMAIL_11676]  
 
Laura Mkumba , MSc GH 
Prevention Research Specialist  
HPTN Leadership and Operations Center  
FHI [ADDRESS_815053]. Suite 200  
Durham , NC [ZIP_CODE]  
Phone:  [PHONE_10232]  
Email: [EMAIL_11677]  
 
Leah Schrumpf, MSc  
Clinical Research Manager   
HPTN Leadership and Operations Center  
FHI [ADDRESS_815054]. Suite 200  
Durham , NC [ZIP_CODE]  
Phone:  [PHONE_10232]  ext. [ZIP_CODE]  
Email: [EMAIL_11678]  
 
Lynda Emel, PhD  
Associate Director, HPTN Statistical and Data 
Management Center  
Fred Hutchinson Cancer Research Center  
[ADDRESS_815055] North M2 -C118  
Seattle, WA [ZIP_CODE]  
Phone: 206 -667-5803  
Email: [EMAIL_5010]  
 
CoVPN 5002 , Version 2.0  Page 8 of 48 
26 May 2021  Maggie Brewinski Isaacs, MD, MPH, FAAP, 
FACPM  
Medical Officer  
NIH/NIAID/DA IDS/VRP/VCRB  
[ADDRESS_815056], 9C44, MSC 9829  
Rockville, MD [ZIP_CODE] -9829  
Phone: 301 -761-7009  
Email: [EMAIL_11679]  
 
Mark Marzinke, PhD   
Analytical Pharmacologist  
HPTN Laboratory Center  
Johns Hopkins University  
Department of Pathology  
[ADDRESS_815057]  
Sheikh Zayed Tower, Room B1 -1020F  
Baltimore, MD [ZIP_CODE] [LOCATION_003]  
Phone: 443 -287-7516  
Email: [EMAIL_2690]   
 
Melissa M. Turner, MSW, LICSW, MPA  
HPTN Community Working Group Liaison  
Washington Veterans Affairs Med ical Center  
[ADDRESS_815058] NW (151B)  
Washington, DC [ZIP_CODE]  
Phone:  [PHONE_12702]  
Email:  [EMAIL_11680]  
 
Nirupama Deshmane Sista, PhD  
Director, HPTN  
Leadership and Operations Center  
FHI [ADDRESS_815059]. Suite 200  
Durham , NC [ZIP_CODE]  
Phone:  [PHONE_12703] ext. [ZIP_CODE]  
Email: [EMAIL_11681]  
 
Pamina M. Gorbach, MHS, DrPH  
Epi[INVESTIGATOR_614611], David Geffen 
School of Medicine  
University of [LOCATION_004], Los Angeles  
CHS 41 -295  
Los Angeles , CA [ZIP_CODE]  
Phone: 310 -794-2555  
Email: [EMAIL_11682]  
 
 
 
 
 Sahar Zangen eh, PhD  
Protocol Statistician  
RTI International  
[ADDRESS_815060], [PO_BOX]  
Research Triangle Park, NC, [LOCATION_002] 
[ZIP_CODE] -2194  
Email: [EMAIL_11683]  
 
Shahnaz Ahmed  
QA/QC Coordinator HPTN Lab Center  
Johns Hopkins University  
[ADDRESS_815061] Pathology 311  
Baltimore, MD [ZIP_CODE]  
Phone:  [PHONE_12704]  
Email:  [EMAIL_11684]  
 
Sten Vermund, MD, PhD  
HPTN Executive Committee Liaison  
Yale School of Public Health  
PO Box [ADDRESS_815062] [ZIP_CODE] -3201  
Phone:  [PHONE_12705]  
Email: [EMAIL_11685]  
 
Susan Eshleman, MD/ PhD 
Virologist, HPTN Laboratory Center  
Johns Hopkins University School of  
Medicine  
[ADDRESS_815063].  
Ross Building, Room 646  
Baltimore MD, [ZIP_CODE]  
Phone: 410 -614-4734  
Email: [EMAIL_2665]  
 
Timothy Skalland,  PhD   
Protocol Statistician  
HPTN Statistics and Data Management Center   
Fred Hutchinson Cancer Research Center  
[ADDRESS_815064] N   
Seattle, WA [ZIP_CODE]   
Phone: 206 -667-1186   
Email:  [EMAIL_11022]  
 
Wafaa El -Sadr, MD, MPH  
Co-Princip al Investigator, HPTN  
ICAP at Columbia University  
Mailman School of Public Health  
[ADDRESS_815065] , Room 1312  
[LOCATION_001], NY [ZIP_CODE]  
Phone: (212) 342 -0505 
Email: [EMAIL_11686]  
CoVPN 5002 , Version 2.0 Page 9 of 48 
 26 May 2021  CoVPN 500 2 
 
SARS -COV -2 PREVALENCE STUDY  
 
SCHEMA  
 
Design:  
Cross -sectional surveys of (1) adults residing in senior living facilities  and attending  outpatient healthcare 
facilities , and (2) the general population in each selected research site community . 
 
Population:  
1) Adults residing in senior living facilities  (nursing home s, assisted or independent living  facilities)  and 
attending outpatient healthcare facilities in neighborhoods of selected research sites  
2) Adults and children (> 2 months of age)  in neighborhoods of selected research sites  
 
Study Size:  
For each research site, up to 3,920 individuals will be enrolled from  one, two, or all three of the following 
populations  (must include at least community ven ues):  
 
1) senior living facilities ( nursing homes , assisted  or independent  living facilities ; n = 500)  
2) outpatient healthcare facilities (n = 500)  
3) community venues  distributed across four age categories  (0-17, 18-39, 40 -59, 60+ years) (n = 730 per 
stratum or 2920)   
 
Total sample size = 3,920 x up to  20 clinical research sites  
 
Study Duration:  
Approximately sixteen  (16) months for overall project. Two (2) months for protocol development and 
institutional review board ( IRB) approval, followed by:  
 
1) Facility -based surveys: 12 months ( 3 months for site preparation and initiation, 3 month s for 
enrollment/sample collection , 4 months for shippi[INVESTIGATOR_614612] *, 2 months for close -out), 
concurrent with  
2) Time -location sam pling (TLS) surveys: 14 months ( 3 months for site preparation and initiation, 6 
months for enrollment/sample collection, 6 months for shippi[INVESTIGATOR_614612] *, 2 months for 
close -out) 
 
*Some activities will be concurrent with enrollment  
 
Study Loca tion:  
Catchment areas surrounding US-based  Clinical Research Sites (CRSs)  of the: HIV Prevention Trials Network 
(HPTN), HIV Vaccine Trials Network (HVTN), Infectious Diseases Clinical Research Consortium (IDCRC),  
International Maternal Pediatric Adolescent AIDS Clinical Trials  Group  (IMPAACT), and the AIDS Clinical 
Trials Group (ACTG) ; to be specified in the Site Announcement Memo  
 
Study Methods:  
Blood collection for SARS -CoV -2 antibody testing and characterization of  the serologic response to SAR S-
CoV -2 infection ; nasal mid -turbinate swab collection for SARS -CoV -2 RNA testing; collection of saliva  in a 
subset of participants  to evaluate the performance of diagnostic SARS -CoV -2 assays using these matrices; 
administration of tablet -based survey. Med ical records abstraction for senior living facility participants  who 
are unable to respond to the study survey . 
CoVPN  5002 , Version 2.0  Page 10 of 48 
26 May 2021    
 
Primary Objective:  
To estimate the prevalence of SARS -CoV -2 IgG seropositivity among individuals in communities surrounding 
selected NIAID clinical research sites  
Secondary Objectives:  
1) To estimate prevalence of SARS -CoV -2 infection based on results of SARS -CoV -2 RNA testing  
2) To estimate prevalence of SARS -CoV -2 infection by [CONTACT_614628] -19 
3) To estimate seroprevalence of SARS -CoV -2 among :  
a. Those without past or current symptoms consistent with COVID -[ADDRESS_815066] with 
confirmed or presumed cases  
c. Those with history of co -morbid medical conditions  
4) To assess association between demographic, clinical and social factors with SARS -CoV -2 infection 
and seroprevalence  
5) To esti mate potential size of populations for referral to COVID -19 prevention and treatment studies  
6) To assess knowledge , attitudes , and behavior  about SARS -CoV -2 and COVID -19 
7) To assess performance characteristics of PCR -based and serologic SARS -CoV -2 tests using saliva  
samples   
Exploratory Objectives:   
1) To model epi[INVESTIGATOR_614613] -19 in the study communities, including modeled 
incidence and prevalence of COVID -19.  
 
2) To conduct laboratory testing in  a subset of participants to characterize SARS -CoV -[ADDRESS_815067] response to SARS -CoV-2 infection ; this may include testing for  SARS -CoV -[ADDRESS_815068] the specificity of SARS -CoV -2 serologic assays.  
 
  
CoVPN  5002 , Version 2.0  Page 11 of 48 
26 May 2021  
 INTRODUCTION  
 
1.1 Background  and Rationale  
 
Currently, the [LOCATION_002] ( US) has far more confirmed COVID -19 cases than any other country. 
The US epi[INVESTIGATOR_614614], with many cities and communities experiencing a 
disproportionately high disease burden and mortality. For example, at present, Minneapolis, Houston , 
Atlanta, and Durham NC , are projected to bear  the brunt of the US epi[INVESTIGATOR_614615], other 
communities may see an increase in the number of COVID -19 cases.  
 
There is an urgent need to address th e COVID -19 pandemic in a multipronged, expeditious manner to 
identify effective interventions for COVID -19 treatment and prevention. The National Institute of 
Allergy and Infectious Diseases (NIAID) has therefore mobilized its major research networks  under 
the banne r of the COVID -19 Prevention Network (CoVPN)  to work together in the rapid evaluation of 
COVID -[ADDRESS_815069] and the Infectious 
Diseases Clinical Research Consortium (IDCRC), will accelerate recruitment, diversify the trial 
cohort s, and build capacity for the conduct of fu ture COVID -19 treatment and prevention studies. In 
this protocol, the terms ‚Äúclinical research site (CRS)‚Äù and ‚Äúresearch site‚Äù and ‚Äúsite‚Äù refer to clinical 
research sites from selected  NIAID networks and ‚Äúcommunity‚Äù refers to the geographic area 
surroundin g each CRS.   
 
The COVID -19 pandemic is evolving, with diverse and dynamic impacts in different regions and 
populations in the US Over the coming months and years, it is likely that different communities will 
experience the epi[INVESTIGATOR_614616], wit h resurgence in other communities. The beginning of 
the US epi[INVESTIGATOR_614617] a nursing home near Seattle, Washington  (1) and 
nursing homes in many other states have had similarly tragic experiences with extremely high 
incidence and mortality rates  (2). The nursing home outbreaks reflect the observation, now noted in 
multiple settings  (2), that COVID -19 is more likely to present as a severe infection among those over 
the age of 65 and those with medical co -morbidities (3) and mortality rates are approximately ten 
times higher for these groups, even among those not living in a skilled nursing facility. These 
morbidity and mortality patterns among older individuals with medical conditions underscore the 
importance of treatment a nd prevention interventions tailored to this population. A ccurate and detailed 
estimates of SARS -CoV -[ADDRESS_815070] substantially higher attack rates and 
higher mortality compared with any other racial or ethnic group (4) across  the US The communities 
surrounding several NIAID CRSs have suffered from not only longstanding racial inequalities, but 
also socioeconomic disparities in housing and  employment, as well as varied access to health and other 
essential services. These populations also have a high prevalence of co -morbidities associated with 
higher incidence of COVID -19 (5-8) , more severe manifestations of COVID -19 disease (9-11), higher 
mortality from COVID -19 (11), and have p oorer health outcomes from a variety of illnesses overall  
(12). As with the observations among the elderly, these racial and ethnic factors all compel the need 
CoVPN  [ADDRESS_815071] of COVID -19 targeted prevention and treatment studies and provision of access to 
these populations of promising prevention and treatment  interventions.   
 
The proposed research will  provide comprehensive information on communities impacted by [CONTACT_4113] -
19 beyond surveillance studies currently in the field (see Appendix IV for summary of existing 
studies). It will  directly contribute to prepared ness for SARS -CoV -[ADDRESS_815072] SARS -CoV -2 infection or evidence of prior SARS -CoV -2 infection (based on results of antibody 
tests, self -report, and medical records). Additionally, data captured through questionnaires about 
participants‚Äô household members with COVID -like illness and deaths, combined with serologic data 
from participants, may also provide information about transmission dynamics within households. 
Questionnaire data will inform estimates of the percent of individuals of different age groups, 
including children, who may have had an asymp tomatic COVID -19 infection. The frequency of 
infection among children and whether infected children play an important role in community 
transmission is poorly understood  (13) . The study  will also provide estimates of the association of 
SARS -CoV -[ADDRESS_815073] been associated with more severe 
disease outcomes and will also identify demographic and social risk factors associated with infection  
(10). Finally, this research  will provide important information about SARS -CoV -2 transmission , 
COVID -19 disease, attitudes about  and uptake of  containment and mitigation measures, racial and 
ethnic health disparities, varied access to testing and public health resources by [CONTACT_614629], prospects for new prevention and treatment strategies , and be used to inform mathematical 
models of disease progression and projection of future COVID -19 risk . 
 
Other SARS -CoV -2 studies  that are ongoing in the US use different sampling ap proaches and/or 
assess different populations (see Appendix IV). For example, the NIH‚Äôs ongoing ‚ÄúSARS -CoV -2 
Pandemic Serosurvey and Blood Sampling,‚Äù ([STUDY_ID_REMOVED]) will estimate the number of adults over 
the age of [ADDRESS_815074] not had confirmed COVID -19 
or known exposure to COVID -19. The study uses non -probability sampling to assemble a cohort of 
15,000 adults from three locations (Bethesda MD, Birmingham AL and Pi[INVESTIGATOR_68321]). The ongoing 
study has a longitudinal co mponent as participants can re -enroll up to four times if more than [ADDRESS_815075], the current study uses time -location sampling to assess cohorts that are representative of 
the communities near NIAID resea rch sites across the US; includes young children and adolescents as 
well as adults; includes a detailed assessment of older adults with medical co -morbidities, including 
those residing in skilled nursing facilities; estimates the number and proportion with active infection as 
well as both symptomatic and asymptomatic prior infection; and will provide a more detailed pi[INVESTIGATOR_614618].  
 
In summary, this study  will provide critically import ant information on the prevalence of current and 
prior SARS -CoV -[ADDRESS_815076] metropolitan areas, one CRS will be 
selected with considerat ion given to the population they serve. For larger metropolitan areas (e.g., New 
York, Chicago, Los Angeles), two or more CR Ss may be selected to gain full representation of the 
region. Adjustments ma y be made to the selected CRSs as the dynamic s of the pa ndemic shift.  
 
The study will begin with community consultations with existing site community advisory boards and 
key stakeholders, including relevant experts from local health departments, local healthcare and social 
service providers, and caregivers for elderly and chr onically ill populations. These consultations will 
help identify specific venues, key community attributes, appropriate social venues, and times and days 
when venues are likely to be well populated. The consultations will also include discussions about how  
best to report results of SARS -CoV -[ADDRESS_815077] using two strategies: facility -based surveys of senior living facilities  and 
time-location sampling (TLS) surveys o f outpatient clinics and community venues. Facility -based 
surveys will begin with each research site creating a list of nearby [CONTACT_614630]. A census of all participating senior living facilities  will be 
conducted  to recruit  up to 500 individuals per research site . Consent will be obtained from legal 
guardians for participant s who are not able to provide consent .  Medical abstraction will be performed 
for these participants in lieu of administering the study questionnaire.  
 
Adults attending outpatient medical clinics and members of t he general population attending 
community v enues will be recruited through TLS. TLS is a well -established study  methodology that 
uses ethnographically -informed mappi[INVESTIGATOR_614619] a ‚Äú clinic -time-day universe‚Äù or 
‚Äúvenue -time-day universe‚Äù of commercial establishments, social service p roviders, schools, places of 
worship, parks, and transit hubs from which a given population can be systematically approached and 
surveyed (14). The approach is appropriate to reach a representative sample of individuals 
participating in social activities and interactions in the study communities.  
 
Adults who were recruited at a selected clinic or venue, have the capacity for consent and are willing 
and able to answer a brief survey and provide a blood sample  and nasal mid-turbinate swab,  will be 
included in the study . Children aged  2 months - 17 years  will be included, with the consent of their 
parent or legal guardian  and their assent from youth 7 ‚Äì 17 years of age ; the parent/guardian will 
complete the questionnaire for those under age [ADDRESS_815078] been 
shown to increase severity and mortality in COVID -19 patients. Data collection from 
parents/guardians about their children is also critical for understanding the prevalence of COVID -[ADDRESS_815079] SARS -
CoV -2 IgG antibodies , evaluated overall and 
by [CONTACT_125916], in the following populations : 
1) Adults 18 and older residing in senior  
living facilities  
2) Adults 18 and older attending outpatient 
healthcare  clinics, and 
3) Individuals in  communities of selected 
research sites in the following age 
categories  
a. 2 months ‚Äì 17years old  
b. 18-39 years old  
c. 40-59 years old  
d. 60 years and older  
 
 
2.2 Secondary Objectives  and Endpoints  
 
Secondary Objectives  Secondary Endpoints  
1) To estimate prevalence of SARS -CoV -2 
infection based on results of SARS -CoV -2 
RNA testing   Proportion of individuals with SARS -CoV -2 
infection  (based on SARS -CoV -2 RNA 
testing ) 
2) To estimate prevalence of SARS -CoV -2 
infection by [CONTACT_614631] -19                     Proportion of individuals with SARS -CoV -2 
infection (based on SARS -CoV -2 RNA 
testing ) who report lack of symptoms versus 
presence of symptoms consistent with 
COVID -19  
3) To estimate seroprevalence of SARS -
CoV -2 among:  
 
a) Those without past or current 
symptoms consistent with COVID -19,  
b) Those with no prior positive SARS -
CoV-[ADDRESS_815080] with confirmed or presumed 
cases , and  
c) Those with history of co -morbid 
medical conditions  Proportion of individuals with SARS -CoV -2 
IgG antibodies who report : 
a) Prior confirmed or presumed COVID -19 
vs. those who report never having 
symptoms ,  
b) No prior COVID -[ADDRESS_815081] with a COVID -19 case (as 
defined by [CONTACT_614632]) , and   
c) Co-morbid medical conditions such as 
obesity, hypertension and diabetes   
CoVPN  5002 , Version 2.0  Page 15 of 48 
26 May 2021  Secondary Objectives  Secondary Endpoints  
4) To assess association between 
demographic, clinical and social factors 
with SARS -CoV -2 infection and 
seroprevalence  Socioeconomic, demographic and clinical 
correlates of COVID -19 and/or SARS -CoV -[ADDRESS_815082] in 
racial and ethn ic health disparities    
5) To estimate potential size of 
populations for referral to COVID -19 
prevention and treatment studies  Extrapolated population sizes of  
a) Those with active COVID -19,  
b) Those who have serologic evidence of 
recent and/or past SARS -CoV -2 
infection, and  
c) Those who have negative RNA and 
serologic SARS -CoV -2 tests  
6) To assess knowledge , attitudes , and 
behavior  about SARS -CoV -[ADDRESS_815083] orders,  
social distancing, and mask use   
7) To assess performance characteristics of 
PCR -based and serologic SARS -CoV -2 tests 
using saliva   a) Estimates of sensitivity, specificity, 
and concordance of SARS -CoV -
assays using  saliva  samples, 
compared to nasal swab and serum 
samples   
b) Estimates of sensitivity and 
specificity of SARS -CoV -2 IgG 
serologic assays using  saliva  samples, 
compared to serum sa mples  
 
 
2.3 Exploratory Objectives  
 
Exploratory Objective 1:  
‚Ä¢ To model epi[INVESTIGATOR_614613] -19 in the study communities, including 
modeled incidence and prevalence of COVID -19.  
 
Exploratory Objective 2:  
‚Ä¢ To conduct l aboratory testing in a subset of participants to characterize SARS -CoV -[ADDRESS_815084] operating procedures 
or other procedures manuals.  
 
3.1 Inclusion Criteria  
 
 Adults residing in senior  living facilities or attending outpatient healthcare facilities  
 
[IP_ADDRESS]  At least 18 years of age  
 
[IP_ADDRESS]  Willing and able to provide informed consent  or consent has been provided by [CONTACT_399840]  (for those with mental incapacity  in senior  living facilities ) 
 
[IP_ADDRESS]  Recruited from a selected facility  
 
 Adults and children from select neighborhoods of research site communities  
 
[IP_ADDRESS]  Adults and children > 2 months of age  
 
[IP_ADDRESS]  For individuals < [ADDRESS_815085] be present  (in person or by [CONTACT_614633] 15 ‚Äì 17 years old ) 
 
[IP_ADDRESS]  Willing and able to provide consent  (or assent for individuals 7-17 years old , 
parent/guardian will provide consent  for all minors ) 
 
[IP_ADDRESS]  Recruited from a selected venue  
 
3.2 Exclusion Criteria  
 
 Previous enrollment in this study , either from the same or another CRS community.  
 
 Any condition that, in the opi[INVESTIGATOR_614620], would make participation in the study 
unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving 
the study objectives.  
Note ‚Äì COVID -[ADDRESS_815086] enroll participants from the community venues.  Each study site will tailor community 
engagement  and recruitment strategies to local circumstances and strategies using the recruitment 
guidelines outlined below  and the Study Specific Procedures (SSP) Manual in order to maximize 
enrollment . Sites will be expected to work closely with community -based organiz ations or other 
appropriate groups with ties to the study communities.  
 
CoVPN  5002 , Version 2.0  Page 17 of 48 
26 May 2021  
 Sampling Design and Recruitment at Community Venues  
 
The initial sampling ‚Äúuniverse‚Äù ‚Äì the list of target  venues in the catchment area of the CRS  ‚Äì is 
comprised of venues routinely frequented by [CONTACT_614634] . A venue could be retail 
businesses (e.g., laundromats, grocery  stores ), cafes and restaurants, health clubs, social service 
providers, schools, places of worship, transit hubs , parks, or beaches. Once this list (the ‚Äúuniverse‚Äù) of 
potential venues is created, CRS staff will determine the suitability of each venue.  A venue may not be 
suitable for sampling if any of the following are true:  
 
‚Ä¢ It would be impossible logistically to recruit, interview and conduct study pro cedures .  
‚Ä¢ Venue owner(s) refuse to allow the project staff access to venue attendees.  
 
Project staff will assess venue suitability by [CONTACT_614635]/managers. Time-location sampling will be used to select individuals 
who attend the population of suitable  community venues  in the catchment area  during the overlappi[INVESTIGATOR_614621]. For each catchment area, we first 
create a list of all suitable community venues  and times that each venue  is available in a given calendar 
period, e.g. week. Sampling  will be performed in two stages. The first stage selects a stratified random 
samp le of Venue Day Times (VDTs; approximate 4-hour time block that is available for recruitment at 
a specified venue) . The second stage samples individuals from sampled VDTs (details outlined in the 
SSP Manual ).  
 
 Sampling Design and Recruitment at Outpatient  Clinics  
 
Time-location sampling will be used to select individuals who attend suitable (where recruitment is 
feasible, and management is amenable)  outpatient medical clinics in the catchment area during the 
overlappi[INVESTIGATOR_614622]. Sampling will be performed in two 
stages. The first stage randomly selects  Clinic Day Times (CDTs; approximate 4 -hour time block that 
is available for recruitment at a specified clinic) . The second stage samples individuals attending the  
clinic  during the selected CDT (details outlined in the SSP Manual ).  
 
 Sampling Design and Recruitment at Senior Living Facilities   
 
Sample and recruitment will be undertaken using a  convenience sample of n= 500 individuals from the 
total population of individuals residing in interested and consenting senior  living facilities  (details 
outlined in the SS P Manual).   
 
3.[ADDRESS_815087] (I oR) or designee may  also withdraw participants from the study in 
order to protect their safety and/or if they are unwilling or unable to comply with required study 
procedures. Participants who withdraw from the study prior to completing the study procedures will be  
replaced. S tudy staff will record the reason(s) for all withdrawals from the study in participants‚Äô study 
records.  
CoVPN  [ADDRESS_815088] result will be transmitted in a confidential manner to local health 
authorities.  
 
 Protocol -Specific Consent Form 
 
Recruiters will obtain informed consent using encrypted electronic tablets; participants will receive a 
paper copy of the consent form . A sample protocol -specific consent form is located in  Appendix I I: 
Sample Informed Consent Form . (Paper consent may be collected if electronic consent is not 
available.)  
 
Each CRS is responsible for developi[INVESTIGATOR_007] a protocol -specific consent form(s) for local use, based on the 
sample protocol -specific consent forms in Appendix I I: Sample Informed Consent Form . The consent 
form(s) must be developed in accordance with requirements of the followin g: 
CoVPN  5002 , Version 2.0  Page 19 of 48 
26 May 2021  ‚Ä¢ The single IRB ( sIRB ) 
‚Ä¢ CRS‚Äôs institution, and  
‚Ä¢ Elements of informed consent as described in Title 45, CFR Part 46 and Title 21 CFR, Part 50, 
and in ICH E6  (R2), Good Clinical Practice: Consolidated Guidance 4.8.  
 
Study sites are strongly encouraged to ha ve their local Community , Resident or Staff  Advisory 
Board(s) (as appropriate) review their site -specific consent forms. This review should include, but 
should not be limited to, issues of cultural competence, local language considerations, and the level of 
understandability.  
 
The sample informed consent form(s) (ICF [s]) include instructions for developi[INVESTIGATOR_115539].   
 
4.2 Enrollment   
 
The point of enrollment into this study is when the participant signs the informed consent form . 
 
4.3 Questionnaire  Administration  
 
The questionnaire will be administered to each consenting participant (or to the parent of participants 
up to 9 years  of age ) using encrypted tablet computers  or paper forms . Data collected will include 
basic demographic, soci oeconomic, geographic, clinical, and household SARS -CoV -2 
exposure/infection history indicators. (The list of COVID symptoms is include d as part of  the 
questionnaire .) A brief knowledge and attitudes questionnaire will be administered to participants aged 
[ADDRESS_815089] from 
COVID -19, such as loss of employment or housing, and access to basi c resources and healthcare.  The 
questionnaire will be tailored for age appropriateness.  
 
4.4 Phlebotomy  
 
A small volume of venous blood ~6 mL for participants aged 2 -6 years, ~10 mL for participants aged 
> [ADDRESS_815090]  unsuccessful attempts at venous 
punc ture (number of failed attempts defined in the SSP)  ), and ~500uL  of blood via heel or finger stick 
(heel stick recommended for  participants 2 -6 months  and finger stick for participants 6 months to 2 
years old ) will be collected from each participant by [CONTACT_614636] a study ID. 
Specimens will be kept in a temperature -controlled container at the venue until they are transported to 
a local laboratory.  
 
Dried blood spots , and plasma or serum aliquots will be prepare d at the processing laboratory and 
stored.  Stored samples will be used  for serologic testing and will also be stored for specialized SARS -
CoV -2 testing. Serologic testing will be performed retrospectively at the LC and/or oth er centralized 
network laboratories. The results of these tests will not be returned to study sites or participants.  
 
4.5 Nasal Mid-Turbinate Swab Sample  Collection  
 
SARS -CoV -2 RNA testing will be performed on nasal mid-turbinate swab samples for analysis at 
local laboratories using  a testing platform approved by [CONTACT_208025]. Procedures for sample collection and 
processing will be described in the SSP Manual.  
 
4.6 Saliva Substudy  
 
CoVPN  5002 , Version 2.0  Page 20 of 48 
26 May 2021  In a subset (appro ximately 1000) of participants, a n additional nasal mid -turbinate swab and s aliva will 
be collected as described in the SSP manual .  
 
4.7 SARS -CoV -2 Counseling  
 
All study participants will receive counseling messages consistent with the US Center for Disease 
Control  and Prevention  (CDC) and local public health authorities. These messages will include 
instructions on use of masks and how to isolate from others, dur ation of isolation, how to monitor for 
worsening of symptoms, and how to connect to social services as needed.  
 
4.8 SARS -CoV -2 Results Reporting  
 
Participants will be provided with instructions to  retrieve the results of their SARS -CoV-2 RNA testing;  
those wit h positive test results will receive counseling about isolation and referral to care and will be 
reminded of plans to inform local health authorities for follow -up and contact [CONTACT_144842]. Positive RNA 
results will be reported to local health authorities  as pe r local health regulations . Serology results are for 
research purposes only and will not be returned to participants.  
 
4.[ADDRESS_815091] been consented by [CONTACT_614637] . Questionnaire domains will include history of chronic illnesses (e.g. diabetes, hypertension, 
asthma, etc.), smoking history, and prior SARS -CoV -2 diagnosis  and will be comparable  (when 
possible)  to domains in the questionnaire .   
 
 SAFETY MONITORING AND ADVERSE EVENT REPORTING  
 
As this is an observational study, standard adverse event (AE) reporting will n ot be undertaken. The 
study team will monitor for and track serious adverse events (SAEs) related to study procedures and/or 
to participation in the study. Such events that are unexpected  will be reported to the NIAID  Medical  
Officer at the same time as th ey are reported to IRBs according to pre -established written procedures, 
as required by 45 CFR 46. This information will not be recorded on case report forms  (CRFs ) or 
entered into the study database. Data on social harms will be collected as part of the o verall assessment 
of participant safety.   
 
 STATISTICAL CONSIDERATIONS  
 
6.1 Review of Study Design  
 
This is a cross -sectional study  of individuals residing within the vicinity of selected research sites  in 
the [LOCATION_002] who are (i) resid ing in senior  living facilities , (ii) visiting  outpatient clinics  at given 
times ; and ( iii) members of the general population who attend any of the listed community venues at 
given time s. The study aims to estimate prevalence of SARS -CoV -2 infection and IgG seropositiv ity 
separately in each of the se populations (sampling strategies described above) . Given that the three 
primary endpoints and their respective samples are independent, sites may recruit from one, two, or all 
three population groups, depending on site capac ity (sites must enroll from at least the community 
venues) . Consenting and assenting participants  who satisfy the inclusion and exclusion criteria 
described in Section 3.0, will answer a brief survey and provide a blood sample and nasal mid -
turbinate swab (s).  
CoVPN  5002 , Version 2.0  Page 21 of 48 
26 May 2021   
6.2 Sample Size  
 
The sample size is calculated for the primary objective, namely, to estimate the seroprevalence of 
SARS -CoV -2 among individuals and communities where potentia l COVID -19 vaccine or other 
prevention interventions studies may be prioritized.   
 
A sample of up to  500 senior l iving facility  residents will be enrolled  (described above).  
 
A separate  sample of approximately 500 adults from outpatient clinical facilitie s will be selected 
according to a TLS design implemented as a two -stage random sample  (described above).  
 
The sample size for the TLS sampling was determined based on the minimum sample size needed to 
achieve prespecified margin of error (MOE). This framew ork sets a tolerance, also called the margin 
of error (MOE) for how close we would like the estimated prevalence ùëùÃÇ to be from the true population 
prevalence ùëù. Denoting the MOE by e, this means  
ùëÉùëü(|ùëùÃÇ‚àíùëù|‚â§ùëí)=1‚àíùõº. 
Assuming ùëùÃÇ  can be treated as normally distributed, this statement is equivalent to setting the half -
width of a 100(1‚àíùõº)/ two-sided confidence interval to ùëí=ùëß1‚àíùõº/2‚àöùëâ(ùëùÃÇ) which results in a sample 
size of  
ùëõ‚âàùëß1‚àíùõº/22ùëù(1‚àíùëù)
ùëí2 
Table 1 shows the sample sizes needed to achieve required sample sizes with +/ -5% and +/ -2.5% 
margin of error on estimated prevalence for a range of assumed prevalence of SARS -CoV -2 antibodies 
for simple random samples of infinite population size.  
Table 1. Sample Size requirement (per strata) to achieve +/ - 5% and +/ - 2.5% MOE for a range 
of assumed seroprevalence  
SARS prev  0.02 0.05 0.1 0.15 0.2 0.25 
+/- 5% MOE  30 73 138 196 246 288 
+/- 2.5% MOE  120 292 553 [PHONE_12706]  
 
Table 2. Sample Size requirement (per strata) to achieve +/ - 5% and +/ - 2.5% MOE for a range 
of assumed seroprevalence after using a design effect of 2.5.  
SARS prev  0.02 0.05 0.1 0.15 0.2 0.25 
+/- 5% MOE  75 182 346 490 615 720 
+/- 2.5% MOE  [PHONE_12707]  1959  2459  2881  
 
To estimate the prevalence of infection and seropositivity in each of four age strata ( 2 months -17, 18-
39, 40 -59, 60+ years), we assumed the seroprevalence of SARS -CoV -2 may vary from 2.5% to 25%, 
and specified a margin of error (MOE) of 2.5% for prevalence b elow 5% and 5% MOE for prevalence 
between 10 and 25%, and assumed a design effect of 2.5 to account for clustering within social 
CoVPN  5002 , Version 2.0  Page 22 of 48 
26 May 2021  networks of a venue . These values are shaded in Table 2 above and yield a maximum sample size of 
730 per stratum.  
 
6.3 Statistical Analyses  
 
This section briefly describes the final study analyses. Detailed technical specifications of the 
statistical analyses will be described in a separate Statistical Analysis Plan  (SAP) . 
 
All statistical analyses will account for the sample design to create the base sampling weights.  The 
sampling weights will be further adjusted for nonresponse and post -stratified using demographic  
information such as  age, sec, race/ethnicity, education, an d income . County -level estimates from the 
census bureau will be used for raking and post -stratification.  We will estimate prevalence and calculate 
95% confidence intervals of SARS -CoV -2 infection and IgG seropositivity for each target population 
separately , i.e. among community residents in each of the age groups  (2 months -17, 18 -39, 40 -59, 60+ 
years) ; among patients attending  the outpatient  clinics;  and among senior living facility  residents . 
 
 Primary Analyses  
 
Design -based  estimates using the survey weights will be used to estimate the overall p revalence of 
SARS -CoV -[ADDRESS_815092] 95% confidence intervals.  
 
Prevalence estimates in each age group will be estimated u sing domain estimates  implemented as ratio 
estimates in each subgroup .  
 
Sensitivity analysis may be considered to adjust for test sensitivity and specificity if prevalence is 
estimated to be lower than 5% . 
 
 Secondary Analyses  
 
Prevalence estimates in each  age group will be estimated using domain estimates implemented as ratio 
estimates in each subgroup  (15) for Secondary Objectives [ADDRESS_815093] CONTAINMENT  
 
7.1 Specimen Collection  
 
Specimens collected during study visits  are specified in Appendix I: Schedule of Evaluation and 
Procedures, and  include:  
 
1) Up to 10 m L blood  (500 uL for participants 2 months to 2 years, ~6 mL for participants aged 2 -6 
years, ~10 mL for participants aged >6 years , or 1  mL from fingerstick after unsuccessful venous 
puncture attempts )) 
2) Note: Dried blood spots will be prepared at the local laboratory for participants less than 2 years of 
age or for participants > 2 years  with unsuccessful venous puncture attempts  
3) Nasal mid-turbinate swab s  
4) Saliva and additional nasal swab samples  (subset of participants  in sal iva substud y) 
 
Specimen collection procedures are described in the SSP Manual. Nasal and saliva  sample collection 
are described in the clinical section of the SSP Manual.  
 
7.2 CRS Lab Procedures  
 
The SSP Manual provide s further guidelines for operational issues concerning the clinical and 
processing laboratories. These documents include guidelines for specimen collection, special 
considerations for phlebotomy, specimen labeling, whole blood  processing, SARS -CoV -2 
screening/ RNA  testing , and general screening.  
 
 All assays described below with the exception of SARS -CoV -[ADDRESS_815094] ing done a t local clinical 
reference laboratories  will be performed for research use only. Individual participant level r esults from 
these assays will not be made available to study sites or participants.  
 
7.3 Endpoint Assays  
 
For SARS -CoV -2 infection, RNA testing will be performed using nasal mid-turbinate swabs at local  or 
clinical reference laboratories using a laboratory platform approved by [CONTACT_208025].  
 
For SARS -CoV -2 seroprevalence, SARS -CoV -2 specific IgG antibodies will be evaluated in 
centralized laboratories approved by [CONTACT_614638] 
(FDA )-approved or have Emergency Use Authorization ( EUA ) from the US FDA.  The SARS -CoV -[ADDRESS_815095] specialized laboratory testing . This testing will be performed 
using samples from a subset of study participants. T his testing may include characterization of SARS -
CoV -2 virus es; phylogenetic analysis; detection of anti -SARS -CoV -2 IgM antibodies; evaluation of 
CoV -2 assays using alternate sample types; characterization of  the host response to SARS -CoV -2 
infection; viral neutralization assays; and the prevalence of co -infections  with other viruses, including 
viruses that may impact the specificity of COVID -19 serologic assays.  
 
Samples may also be used for other testing and research related to furthering the understanding of 
SARS -CoV -2 immunology and virology, including, but not limited to, antibody -mediated anti -viral 
activities, and antibody dependent enhancement; monoclonal antibodies and antibody -mediated 
CoVPN  5002 , Version 2.0  Page 24 of 48 
26 May 2021  prevention; or vaccines. In addition, samples may be used to perform additional assays to support 
standardization and validation of existing or newly -developed test methods.  
 
7.[ADDRESS_815096]  one year after the primary manuscript has been published.   
 
Other use of specimens is defined as  studies not covered by [CONTACT_270809] (see Appendix I I: Sample Informed Consent Form : Sample Informed Consent 
Form ).  
 
This research may relate to SARS -CoV -2, COVID -19, vaccines, antibodies, the immune system, and 
other diseases. This research is done only to the extent authorized in each study site‚Äôs informed 
consent form, or as otherwise authorized under applicable law. Ot her research on specimens (‚Äúother 
use‚Äù) will occur only after review and approval by [CONTACT_400834], the IRB of the researcher requesting 
the specimens, and the sIRB , if required.  
 
As part of consenting for the study, participants document their initial decision to allow or not allow 
their specimens to be used in other research, and they may change their decision at any time. The 
participant‚Äôs initial decision about other use of thei r specimens, and any later change to that decision, 
are documented in the study database . The Network will only allow other research to be done on 
specimens from participants who allow such use.  
 
CRSs must notify the leadership and operations center ( LOC ) if institutional or local governmental 
requirements pose a conflict with or impose restrictions on specimen storage or other use of 
specimens.  
 
7.[ADDRESS_815097] be 
transported according t o instructions detailed in the  International Air Transport Association Dangerous 
Goods Regulations.  
 
 HUMAN SUBJECTS CONSIDERATIONS  
 
The CoVPN Prevalence Study will rely on the existing DAIDS guidelines  regarding human subjects 
considerations  to maintain  compliance with the expectation of NIAID sponsored clinical research 
studies.    
 
8.1 Ethical Review  
 
This protocol and the template ICF (s) contained in Appendix I I: Sample Informed Consent Form : 
Sample Informed Consent Form,  and Appendix III: Sample Verbal Pre -Screening Script , will be 
reviewed and approved by [CONTACT_614639] (PSRC) with resp ect to 
scientific content and compliance with applicable research and human subjects‚Äô  regulations.  
CoVPN  [ADDRESS_815098] comply with the requirements of 45 CFR 46.108(a)(4) and 21 CFR 
56.108b for promptly reporting the following: all unanticipated problems involving risks to human 
subjects or others ; serious or continuing noncompliance with applicable regu lations or the 
requirements or determinations of their IRBs/ECs; and any suspension of termination of IRB approval . 
Documentation of continuing review will be submitted to the DAIDS PRO , in accordance with the 
current DAIDS Protocol Registration Policy and  Procedure Manual.   
 
8.2 Informed Consent  
 
Informed consent will be obtained from each study participant  using encrypted electronic tablets . 
Paper copi[INVESTIGATOR_614623] a copy with them.  Each study site is 
responsible for de velopi[INVESTIGATOR_614624], based on the template s in 
Appendix I I: Sample Informed Consent Form : Sample Informed Consent Form,  which describes the 
purpose of the study, the procedures to be followed, and the risks and benefits of participation, in 
accordance with all applicable regulations. If applicable, the study site also is responsible for 
translating the template form into l ocal languages and verifying the accuracy of the translation by 
[CONTACT_132780] -translation.   
 
Literate participants will document their provision of informed consent by [CONTACT_614640]. Non -
literate participants will be asked to document their informed consent by [CONTACT_579009] (e.g., with 
an X, thumbprint, or other mark) in the presence of a literate third -party witness. (Further details 
regarding DAIDS requirements for documenting the informed consent process with both literate and 
non-literate participants are provided in the DAIDS Standard Operating Procedure for Source 
Documentation.) Any other IRB requirements and site SOPs  for obtaining informed consent from non -
literate persons also will be followed.  
 
For potential participants  who are not of legal age, the parent or guardian will provide permission and 
the minor  (7-17 years old)  will provide assent.  
 
For individuals with diminished cognitive capacity, study staff will explain the nature of the study, 
including the risks and ben efits, to the participant‚Äôs legally authorized representative (LAR), and to the 
extent possible to the participant, and answer all questions regarding the study. The LAR and the 
participant will be informed that their participation is voluntary. The LAR wi ll complete an electronic 
informed consent that meets all applicable  local and regulatory requirements. Due to strict COVID -19 
prevention measures in  senior living  and healthcare facilities, alternative methods of obtaining consent 
from LARs  (for example, by [CONTACT_648]) will be allowed if approved by [CONTACT_1201]. Study staff will document 
the consent process in the participants‚Äô files for all enrolled participants.  
 
The study staff member obtaining the informed consent and, if applicable, the individual designated to 
witness a verbal consent, must also sign the ICF.  The participant or LAR must complete a 
comprehension assessment prior to signing the consent form.  
 
CoVPN  [ADDRESS_815099] participant privacy  and 
confidentiality, it is possible that participants' involvement in the study could become known to others, 
and that social harms may result  because of presumed or confirmed SARS -CoV2 infection .  
 
8.[ADDRESS_815100] -
protected access systems. Forms, lists, logbooks, appointment books, and any other listings that link 
participant ID numbers to other identifying information will be stored in a separate, l ocked file in an 
area with limited access.  
 
Participant‚Äôs study information will not be released without the written permission of the participant, 
except as necessary for monitoring by [CONTACT_614641]/or its contractors; representatives of the study‚Äôs  
LOC , SDMC , and/or  LC, and the sIRB.   
 
NIAID  has Certificate s of Confidentiality from the US Department of Health and Human Services that 
is applicable to this study. Certificates cover all study sites conducting this research, regardless of the 
country where the in vestigator or the protected information resides. This Certificate protects study 
staff from being compelled to disclose study -related information  held in the US,  by [CONTACT_579015], State 
or local civil, criminal, administrative, legislative, or other body .  
 
CoVPN  5002 , Version 2.0  Page 27 of 48 
26 May 2021  8.7 Communicable Disease Reporting Requirements  
 
Study staff will comply with all applicable local requirements to report communicable diseases  
(including SARS -CoV-2 infections , where required ) identified among study participants to local health 
authorities. Participants will be made aware of all reporting requirements during the study informed 
consent process.  
 
8.[ADDRESS_815101] the protocol and protocol ICF(s) approved, as 
appropriate, by [CONTACT_17359]. Upon receiving final approval, sites will submit all required protocol 
registration documents to the DAIDS PRO at the DAIDS Regulatory Support Center ( RSC ). The 
DAIDS PRO will review the submitted protocol registration packet to ensure that all of the required 
documents have been received. In the case of Initial Registration, site -specific ICFs WILL be reviewed 
and approved by [CONTACT_68410]. Sites will receive an Initial Registration Notification fr om the 
DAIDS PRO that indicates successful completion of the protocol registration process. A copy of the 
Initial Registration Notification should be retained in the site's regulatory files.  
 
Following Initial Registration, any full protocol amendments req uire submission of a protocol 
registration packet to the DAIDS PRO as described above; however, the DAIDS PRO WILL NOT  
review and approve site -specific ICFs. Sites will receive a Registration Notification when the DAIDS 
PRO receives a complete registration  packet.  Upon receiving final IRB/EC and any other applicable 
regulatory  approval(s) for an amendment, sites should implement the amendment immediately.  
 
For additional information on the protocol registration process and specific documents required for 
initial and amendment registrations, refer to the current version of the DAIDS Protocol Registration 
Manual  online.  
 
9.2 Study Activation  
 
Pending successful protocol registration and submission of all required documents, the LOC  staff will 
‚Äúactivate‚Äù a site. Study implementation may not be initiated until a study activation notice is provided 
to the site by [CONTACT_614642] . In addition, if study act ivation is determined to be necessary for any subsequent 
amendments, study implementation may not be initiated until a study activation notice is provided to 
the site by [CONTACT_614642] . 
 
9.3 Study Coordination  
 
Study implementation will be directed by [CONTACT_3181] a s well as the SSP  Manual .  The SSP  Manual  
‚Äî which will contain links to the Requirements for Source Documentation in DAIDS Funded and/or 
Sponsored Clinical Trials, as well as the DAIDS Manual for Expedited Reporting of Adverse Events 
CoVPN  5002 , Version 2.0  Page 28 of 48 
26 May 2021  to DAIDS and the DAIDS  Table for Grading the Severity of Adult and Pediatric Adverse Events ‚Äî 
will outline procedures for conducting study visits; data and forms processing; AE assessment, 
management and reporting; and other study operations.  
  
Data collection instruments and ot her study -specific implementation materials will be developed by 
[CONTACT_614643]. Data will be submitted to the SDMC for data cleaning, 
reporting and analysis. Data  management and coding queries will be generated and applied to th e data 
by [CONTACT_614644] a routine basis for verification and resolution  by [CONTACT_6624] .   
 
Close coordination between protocol team members will be necessary to track study progress, respond 
to queries about proper study implementation, and address other is sues in a timely manner. Rates of 
accrual and  visit completion rates  will be monitored closely by [CONTACT_614645].  
 
9.4 Study Monitoring  
 
 Study monitoring will be performed at the discretion of and in accordance with DAIDS policies. 
Study monitors will:  
 
‚Ä¢ Verify compliance with human subjects and other research regulations and guidelines;  
‚Ä¢ Assess adherence to the study protocol, SSP Manual , and local counseling practices; and  
‚Ä¢ Confirm the quality and accuracy of information collected at the study site and entered into the 
study database.  
‚Ä¢ Verify compliance with Good Clinical Laboratory Practices  
 
Monitoring visits will be conducted on -site or remotely. Remote visits may include r emote source 
document verification using methods specified for this purpose by [CONTACT_18127]. Remote monitoring visits 
may be performed in place of, or in addition to onsite visits to ensure the safety of study participants 
and data integrity  (16). The site will make available study documents for site monitors to review 
utilizing a secure platform that is HIPAA and 21 CRF Part 11 compliant. Potential platform options 
include: Veeva SiteVault, site -controlled SharePoint or cloud -based portal, direct  access to Electronic 
Medical Record (EMR), and Medidata Rave Imaging Solution. Other secure platforms that are 21 CFR 
Part 11 compliant may be utilized, as allowed by [CONTACT_163423] 
(OCSO).  For on -site visits s ite investigator s will allow study monitors to inspect study facilities and 
documentation (e.g., ICFs, clinic and laboratory records, other source documents, paper or electronic 
CRFs), as well as observe the performance of study procedures. Investigators also will allow 
inspection of all study -related documentation by [CONTACT_614646]‚Äôs  LOC, 
SDMC, and LC, as well as NIAID, the sIRB and US regulatory authorities (Office for Human 
Research Protections (OHRP) or other regulatory agencies). A site visit log will be maintained at each 
study site to document all visits.   
 
9.[ADDRESS_815102] be 
submitted to the DAIDS RSC and approved by [CONTACT_56335](s) prior to implementing  the 
amendment.  
 
 
CoVPN  5002 , Version 2.0  Page 29 of 48 
26 May 2021  9.6 Investigator‚Äôs Records  
 
The IoR will  maintain, and store in a secure manner, complete, accurate, and current study records 
throughout the study. The IoR will retain all study records for at least three years after the completion 
of research.  
 
Completion of a clinical research study occurs when the following activities have been completed:  
 
‚Ä¢ All research -related interventions o r interactions with human subjects (e.g., when all subjects 
are off study);  
‚Ä¢ All protocol -required data collection of identifiable private information described in the IRB -
approved research plan;  
‚Ä¢ All analysis of identifiable private information described in the IRB -approved research plan;  
‚Ä¢ Primary analysis of either identifiable private or de -identified information.  
 
Study records include administrative documentation ‚Äî including protocol registration documents and 
all reports and correspondence relating to the study ‚Äî as well as documentation related to each 
participant screened and/or enrolled in the study ‚Äî including  ICFs, locator forms, eCRFs, notations of 
all contacts with the participant, and all other source documents.  
 
9.[ADDRESS_815103] to the NIH Policy on the Dissemination of NIH -Funded Clinical Trial 
Information. A description of this clinical trial will be available on www.ClinicalTrials.gov.  
  
CoVPN  5002 , Version 2.0  Page 30 of 48 
26 May 2021  
 REFERENCES  
 
1. McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, et al. Epi[INVESTIGATOR_376183] -19 in a Long -Term Care Facility in King County, Washington. New England Journal of Medicine. 
2020;382 (21):2005 -11. 
2. COVID -19 Nursing Home Data [Internet]. 2020 [cited 06/08/2020]. Available from: 
https://data.cms.gov/stories/s/COVID -19-Nursing -Home -Data/bkwz -xpvg . 
3. CDC . Coronavirus Disease 2019 (COVID -19): Groups at Higher Risk for Severe Illness 2020 
[updated 05/14/2020. Available from: https://www.cdc.gov/corona virus/2019 -ncov/need -extra -
precautions/groups -at-higher -risk.html . 
4. Millett GA, Jones AT, Benkeser D, Baral S, Mercer L, Beyrer C, et al. Assessing Differential 
Impacts of COVID -19 on Black Communities. Annals of epi[INVESTIGATOR_623]. 2020.  
5. Fei K, Rodriguez -Lopez JS, Ramos M, Islam N, Trinh -Shevrin C, Yi SS, et al. Racial and 
Ethnic Subgroup Disparities in Hypertension Prevalence, [LOCATION_001] City Health and Nutrition Examination 
Survey, 2013 -2014. Preventing chronic disease. 2017;14:E33.  
6. Osei K, Gaillard T. D isparities in Cardiovascular Disease and Type 2 Diabetes Risk Factors in 
Blacks and Whites: Dissecting Racial Paradox of Metabolic Syndrome. Frontiers in endocrinology. 
2017;8:204.  
7. Petersen R, Pan L, Blanck HM. Racial and Ethnic Disparities in Adult Obe sity in the United 
States: CDC's Tracking to Inform State and Local Action. Preventing chronic disease. 2019;16:E46.  
8. Vahidy FS, Nicolas JC, Meeks JR, Khan O, Jones SL, Masud F, et al. Racial and Ethnic 
Disparities in SARS -CoV -2 Pandemic: Analysis of a C OVID -19 Observational Registry for a Diverse US 
Metropolitan Population. medRxiv. 2020:2020.04.24.20073148.  
9. Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J, et al. Characteristics 
and Clinical Outcomes of Adult Patients Hospi[INVESTIGATOR_21391] -19 - Georgia, March 2020. MMWR 
Morbidity and mortality weekly report. 2020;69(18):[ADDRESS_815104] JM, McGinn T, Davidson KW, et al. 
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospi[INVESTIGATOR_45086] -19 
in the [LOCATION_001] City Area. JAMA. 2020;323(20):[ADDRESS_815105] died 100,000 by [CONTACT_545]/ethnicity group as of April 16, 2020 2020 [  
12. Myers C, Olson C, Kerker B, Thorpe L, Greene C, Farley T. Reducing health disparities in 
[LOCATION_001] City: health disparities in life expectancy and d eath. 2010.  
13. CDC COVID -19 Response Team. Coronavirus Disease 2019 in Children - [LOCATION_002], 
February 12 -April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422 -6. 
14. Karon JM, Wejnert C. Statistical methods for the analysis of time -location sampli ng data. 
Journal of urban health : bulletin of the [LOCATION_001] Academy of Medicine. 2012;89(3):565 -86. 
CoVPN  5002 , Version 2.0  Page 31 of 48 
26 May 2021  15. Lumley T, Kronmal R, Ma S. Relative risk regression in medical research: models, contrasts, 
estimators, and algorithms. 2006.  
 
16. FDA Guidance on Condu ct of Clinical Trials of Medical Products During the COVID -19 Public 
Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards, March 2020, 
Updated on January 27, 2021. Accessed at: https://www.fda.gov/media/136238/download  
 
 
 
 
 
 
 
 
CoVPN  5002 , Version 2.0  Page 32 of 48 
26 May 2021   
APPENDIX I: SCHEDULE OF EVALUATIONS AND PROCEDURES  
 
 
 
 
 
Pre-screening  
Screening  
Enrollment  
Administrative and Behavioral Evaluations/Procedures     
Eligibility pre -screening  X   
Screening and Enrollment informed consent   X  
Demographic and clinical information    X 
Questionnaire administration    X 
COVID -19 risk reduction counseling    X 
Clinical Evaluations/Procedures     
POC COVID -19 testing with return of results (if available)     X 
Collection of nasal  mid-turbinate  swab *   X 
Blood collection    X 
Saliva collection (subset of participants)    X 
Laboratory Evaluations/Procedures     
Local testing:     
SARS -CoV-2 RNA testing ( nasal mid-turbinate swab )    X 
Serum  storage for  SARS -CoV-2 antibody testing and characterization of the 
serologic response to SARS -CoV-2 infection;  and other testing (see Section 
7.4)  
 X 
Dried blood spot storage  for SARS -CoV-2 antibody testing and 
characterization of the serologic response to SARS -CoV-2 infection; and 
other testing , when test s are validated  (see Section 7.4) **  
 X 
Nasal swab  mid-turbinate storage* for the saliva substudy    X 
Saliva sample  storage (subset of participants)    X 
 
*A duplicate set of nasal swab  samples is needed for storage in the Saliva substudy in a subset of participants who  are selected  
at two sites .  
**DBS storage for participants 2 months to 2 years  or >2 years  that had unsuccessful venous puncture attempts  prepared from 
capi[INVESTIGATOR_614625].  
  
CoVPN  5002 , Version 2.0  Page 33 of 48 
26 May 2021  APPENDIX I I: SAMPLE INFORMED CONSENT FORM  
 
CoVPN 5002  
 
SARS -COV -2 PREVALENCE STUDY  
  
Version 2.0  
26 May  2021  
DAIDS -ES ID: [ZIP_CODE]  
 
Sponsored by : [CONTACT_209060] (US) National Institute of Allergy and Infectious Diseases (NIAID), US National 
Institutes of Health (NIH)  
 
Site:  
Principal Investigator : 
[CONTACT_7626] : 
 
NOTE TO SITES : This sample consent form must be modified into three separate consent forms: (1) adults 
enrolling with no diminished cognitive  capacity, that are able to consent on their own  (2) minors , ages 7-17, 
enrolling from community venues, with consent of their guardian and their assent  (signed on this form for ages 
14-17; signed on a separate, simplified assent form for ages 7-13, Appendix III)  and ( 3) individuals  with 
diminished cognitive capacity, with consent given by  [CONTACT_508776] . Guidance is provided 
below, as needed.   
 
Consent form for minors, add:  If you are a parent or legal guardian of a child participating on this study, 
throughout this document ‚Äúyou(r)‚Äù = ‚Äúyour child‚Äù.  
 
Consent form for adults with diminished cognitive capacity , add:  If you are the legally authorized repres entative 
of an individual participating in this study, throughout this document ‚Äúyou(r)‚Äù = ‚Äúthe participant‚Äù.  
 
Thank you for your interest in our research study. Please read this consent form or ask someone to read it to you. 
If you decide to join the stud y, we will ask you to sign or make your mark on this form. We will offer you a copy 
to keep. We will ask you questions to see if we have explained everything clearly. You can also ask us questions 
about the study.  
 
Research is not the same as treatment or  medical care. The purpose of a research study is to answer scientific 
questions.  
 
1. Summary Information  
 
Here is a summary of important information about the study:  
 
The purpose of the study is to estimate the number of people who have or have had the SARS -CoV -2 virus in 
different communities in the [LOCATION_002] . Some people know this virus by [CONTACT_424948] ‚Äúcoronavirus.‚Äù It can cause 
the disease called COVID -19. There is no drug given in this study  for prevention or treatment .  
 
If you choose to join, you will have one study visit  either  right after signing this consent form  or at a later date at 
the clinic . If you are available now, t he visit procedures will take place ri ght here. You will complete a 
questionnaire, provide a blood  sample and have  a nasal swab collected.  Some participants may be asked  to also 
provide  a saliva  sample  and additional nasal swab . [Only include saliva if your site is participating in this subset . 
Otherwise, delete.]  [For participants recruited from health facilities, also include: We will also collect some 
CoVPN  5002 , Version 2.0  Page 34 of 48 
26 May 2021  information from your health records  to document chronic diseases, smoking history, and history of SARS -CoV -2 
diagnosis .]  
 
Some general risks include discomfort when your blood is drawn . Nasal swabs may cause minor irritation to your 
nose, and sneezing and rarely, may cause a nosebleed. You may also feel worried or anxious while waiting for 
your SARS -CoV -[ADDRESS_815106] benefit to you for taking part in this study, but the information learned from this study 
may help researchers develop new ways to prevent and /or treat SARS -CoV -[ADDRESS_815107] of this form provides a more complete description of this study. Please read it carefully.  
 
ABOUT THE STUDY  
 
The COVID -19 Prevention Network (CoVPN) is doing a study to estimate the number of people who have or 
have had the SARS -CoV -[ADDRESS_815108] new drugs for treatment or prevention of 
COVID -19.  
 
Between 78,000 ‚Äì 98,[ADDRESS_815109] udy at multiple places around the country. In each 
community, ~3920  will be enrolled. The researcher in charge of this study in your community is 
[Insert name [CONTACT_107002]]  and s/he is located at  [Insert CRS name] . The [sponsor]  is pay ing for the study.  
 
2. We are doing this study to answer several questions.  
 
‚Ä¢ How many people in the study communities have or have had SARS -CoV-2 or COVID -19? 
‚Ä¢ What do people in the study communities know about SARS -CoV -2 or COVID -19? 
‚Ä¢ How do people in the study communities feel about SARS -CoV -2 or COVID -19? 
‚Ä¢ How often and in what way s are people exposed to SARS -CoV -2?   
‚Ä¢ What is the general health of people in the study communities?  
 
3. There is no drug or treatment provided as part of this study.  
 
This is an observational study. We are only testing participants for SARS -CoV -2, drawing blood for additional 
lab testing related to SARS -CoV -2, and asking participants to complete a questionnaire.   
 
JOINING THE STUDY  
 
4. It is completely up to you whethe r or not you join the study.  
 
Take your time in deciding. If it helps, talk to people you trust such as a friends or family member. If you decide 
not to join this study, or if you discontinue before you complete the study procedures, you will not lose any  
benefits or rights you would normally have at [CRS name ]. 
 
 
CoVPN  5002 , Version 2.0  Page 35 of 48 
26 May 2021   
5. If you want to join the study, we will screen you to see if you are eligible.  
 
Screening involves a brief questionnaire to determine:  
‚Ä¢ Your age  
‚Ä¢ Where you live  
‚Ä¢ If you are enrolled in another SARS-CoV -2 or COVID -19 clinical trial which involves taking an 
experimental medication  
‚Ä¢ If you are already enrolled in this study in another community  
 
BEING IN THE STUDY  
 
If you meet the study requirements and want to join, here is what will happen:  
 
6. You will have one study visit either immediately after signing the consent form or at a later date that is 
more convenient for you.  
 
This study includes a single study visit. It will take approximately 30 minutes to complete the study visit.  (If all 
procedures cannot  be completed in one visit, sample collection and the brief survey must be completed during  the 
same visit within 10 days  of completing this consent ). The study procedures will include:  
 
‚Ä¢ Collec ting basic information about you, your health, your household, and possible exposure to SARS -
CoV -2 (completed by [CONTACT_614647] 0 -9 years old)  
‚Ä¢ Completing a brief survey about your knowledge and feelings about SAR S-CoV -2 (completed by [CONTACT_614648] 0 -9 years old)  
‚Ä¢ Drawing blood for lab testing related to SARS -CoV -2 
o ~10 mL if you are > 6 years old  or 1 ml from a fingerstick after having had unsuccessful venous 
puncture attempts  
o ~6 mL if you are 2 ‚Äì 6 years old   
o ~500 uL in a microtainer tube  if you are 2 months to < 2 years old   
‚ñ™ A heel stick is recommended for participants 2 -6 months and finger stick for  participants 
6 months to 2 years old  
‚Ä¢ Performing nasal swab testing for  SARS -CoV -2 
‚Ä¢ Some participants may be asked to provide  saliva  and an additional nasal swab  for SARS -CoV -2 testing . 
[Only include if your site is participating in this subset. Otherwise, delete.]  
‚Ä¢ [For participants recruited from health facilities, also include: We will also collect some information 
from your health records  related to chronic conditions, smoking history, and prior SARS -CoV -2 
diagnosis .] 
 
7. You will receive a gif t card for  [$X] when you complete the study visit.  
 
This amount is to compensate you for your time. You do not have to pay anything to be in this study.  
 
8. We will test your samples to see if you have or have had SARS -CoV -[ADDRESS_815110] the SARS -CoV -2 virus in your 
body.  You will be given  a [phone number or website ] to retrieve the results of these tests.  We will also test for 
antibodies against SARS -CoV -2. Antibodies are the prote ins your body makes to fight infections. Antibody tests 
will tell us if you have SARS -CoV -[ADDRESS_815111] s are only for research purposes . 
Results from these tests  will not be returned  to you .    
 
CoVPN  5002 , Version 2.0  Page 36 of 48 
26 May 2021  Your samples  may also be used to help characterize  SARS -CoV -2 viruses and the body's response to SARS -CoV -
[ADDRESS_815112] on  COVID -19. These tests are only for research purposes. Results from these tests will 
not be returned to you.    
 
Testing will not include sequencing your full DNA.  
 
9. When samples are no longer needed for this study, the CoVPN may want to use them in other studies 
and share them with other researchers.  
 
These samples are called ‚Äúextra samples‚Äù. The CoVPN will only allow your extra samples to be used in other 
studies if you agree to this. You will mark your decision at the end of this form. If you have any questions, please 
ask. 
 
Do I have to agree?  No. You are free to say yes or no, or to change your mind after you sign this form. At your 
request, we will destroy all extra samples that we have. Your decision will not affect your being in this study or 
have any negative consequences  here.  
 
Where are the samples stored?  Extra samples are stored in a secure central place called a repository. Your 
samples will be stored in a repository in the [LOCATION_002].  
 
How long will the samples be stored?  There is no limit on how long your extra samples will be stored.  [Site: 
Revise the previous sentence to insert limits if your regulatory authority imposes them.]  
 
Will I be paid for the use of my samples?  No. Also, a researcher may make a new scientific discovery or 
product based on the use of yo ur samples. If this happens, there is no plan to share any money with you. The 
researcher is not likely to ever know who you are.  
 
Will I benefit from allowing my samples to be used in other studies?  Probably not. Results from these other 
studies are not g iven to you, this clinic, or your doctor. They are not part of your medical record. The studies are 
only being done for research purposes.  
 
Will the CoVPN sell my samples and information?  No, but the CoVPN may share your samples with other 
researchers. Onc e we share your samples and information, we may not be able to get them back.  
 
How do other researchers get my samples and information?  When a researcher wants to use your samples 
and information, their research plan must be approved by [CONTACT_400834]. Also, th e institutional review board (IRB) 
will review this plan.  IRBs protect the rights and well -being of people in research. If the research plan is 
approved, the CoVPN will send your samples to the researcher‚Äôs location.  
 
What information is shared with the C oVPN or other researchers?  The samples and information will be 
labeled with a code number. The key to the code will stay at the CRS. It will not be shared with the CoVPN or 
other researchers. Your name [CONTACT_107030]. However, some information that we share may 
be personal, such as your race, ethnicity, sex, health information from the study, and lab test results.  
 
What kind of studies might be done with my extra samples and information?  The studies will be related to 
SARS -CoV -2, COVID -19, vaccines, antibodies, the immune system  (your body‚Äôs defense system)  and other 
diseases. Testing will not include sequencing your full DNA.  
 
 
 
CoVPN  [ADDRESS_815113] access to my information in studies using my extra samples?  People who may see your 
information are:  
 
‚Ä¢ Researchers who use your extra samples and information for other research  
‚Ä¢ Government agencies that fund or monitor the research using your extra samples and info rmation  
‚Ä¢ Any regulatory agency that reviews clinical trials  
‚Ä¢ An Institutional Review Board  
‚Ä¢ The people who work with the researcher  
 
All of these people will do their best to protect your information. The results of any new studies that use your 
extra sample s and information may be published. No publication will use your name [CONTACT_107005].  
 
10. We will do our best to protect your private information.  
 
[Sites should verify there are no HIPAA conflicts with this section.]  
Your study records and sa mples will be kept in a secure location. We will label all of your samples and most of 
your records with a code number, not your name [CONTACT_138952]. However, it is possible to identify 
you, if necessary. We will not share your name [CONTACT_614652], or with anyone 
else who does not need to know your name.  
 
Clinic staff will have access to your study records. Your records may also be reviewed by [CONTACT_614649] r rights, keepi[INVESTIGATOR_106785], and following the study plan. These groups 
include:  
 
‚Ä¢ The US National Institutes of Health and its study monitors,  
‚Ä¢ Any regulatory agency that reviews clinical trials,  
‚Ä¢ [Insert name [CONTACT_614653]],  
‚Ä¢ [Insert name [CONTACT_115649]/or national regulatory authority as appropriate] , 
‚Ä¢ The CoVPN and people who work for them,  
‚Ä¢ The US Office for Human Research Protections.  
 
All reviewers will take steps to keep your records private.  
 
We cann ot guarantee absolute privacy. If you are found to have SARS -CoV -[ADDRESS_815114] to report 
the following information:  
 
[Site: Includ e any public health or legal reporting requirements. Bulleted examples should include all 
appropriate cases (reportable communicable disease, risk of harm to self or others, etc.). If your site does not 
have public health or legal reporting requirements, y ou may delete the last sentence in the paragraph above, 
along with the bullets below.]  
‚Ä¢ [Item 1]  
‚Ä¢ [Item 2]  
‚Ä¢ [Item 3]  
 
We have a Certificate of Confidentiality from the US government, to help pr otect your privacy. With the 
certificate, we do not have to release information about you to someone who is not connected to the study, such as 
the courts or police. Sometimes we can‚Äôt use the certificate. Since the US government funds this research, we 
cannot withhold information from it. Also, you can still release information about yourself and your study 
participation to others.  
CoVPN  5002 , Version 2.0  Page 38 of 48 
26 May 2021   
The results of this study may be published. No publication will use your name [CONTACT_107005].  
We may share inform ation from the study with other researchers. We will not share your name [CONTACT_614654].  
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov. This website will not include 
information that can iden tify you. At most, the website will include a summary of the results. You can search this 
website at any time.  
 
11. If you are infected with SARS -CoV -2. 
 
We will direct you to resources you can access if you are feeling sick and information on how to avoid passing 
SARS -CoV -2 to others.  
 
OTHER RISKS  
 
12. There are other risks to being in this study.  
 
Risks of giving blood:  
Taking blood samples may cause so me pain, bruise your arm, or make you feel lightheaded. In rare cases you 
may faint. There is also a slight chance of infection when blood is drawn.  
 
SARS -CoV-[ADDRESS_815115] result.  
 
Completing the questionnaire  
You may become embarrassed, worried, or anxious when completing the survey.  
 
Risk of exposure to SARS -CoV-2 from other people:  
Participating in this research study may increase your risk of exposure to SARS -CoV -2 from other people.  
However, your research site will do everything they can to make this risk as small as possible by [ include details 
of how staff will protect participa nts from exposure].  
 
Risks of disclosure of your personal information:  
We will take several steps to protect your personal information. Although the risk is very low, it is possible that 
your personal information could be given to someone who should not ha ve it. If that happened, you could face 
discrimination, stress, and embarrassment. We can tell you more about how we will protect your personal 
information if you would like it.  
 
BENEFITS  
 
13. The study may not benefit you.  
 
There may be no direct benefits to participating in this study. However, being in the study might still help you in 
some ways. You will receive  the results of your  SARS -COV -[ADDRESS_815116] today. You are free to end the visit  or withdraw your 
consent  at any time and for any reason. Your care at [CRS name ] and your  legal rights will not be affected.   
 
If you choose to leave the study  at a later date , the researchers may keep and analyze the data already collected , as 
long as it relates to the study described in this consent form.  
 
15. You may be removed from the st udy 
 
You may be withdrawn from the study in order to protect their safety and/or if you are unwilling or unable to 
comply with required study procedures.  
 
INJURIES  
 
16. If you get sick or injured because of the study, contact [CONTACT_106986].  
 
It is unlikely that you will be injured as a result of study participation. If you are injured, the [CRS name]  staff 
will give you immediate necessary treatment for your injuries. You [will/will not] have to pay for this treatment. 
You will be told where y ou can get additional treatment for your injuries. [ Must include the following :] There is 
no program to pay money or give other forms of compensation for such injuries either through this institution or 
the US NIH. You do not give up any legal rights by [CONTACT_614650].  
 
QUESTIONS  
 
17. Contact [CONTACT_579046].  
 
If you have questions about this study, contact [contact [CONTACT_3031]]  
 
If you have any symptoms that you think may be related to this study, contact [contact [CONTACT_3031]]  
 
If you have questions about your rights as a research participant, you should contact [insert name [CONTACT_614655]]  at [contact [CONTACT_3031]] . 
 
If you want to be excluded from the study after you‚Äôve completed your study visit, contact [contact [CONTACT_3031]] . 
 
 
CoVPN  5002 , Version 2.0  Page 40 of 48 
26 May 2021  YOUR PERMISSIONS AND SIGNATURE  
[NOTE TO SITES: Delete this section if using a separate consent for use of samples and information in other 
studies]  
 
1. Permission to use extra samples.  
 
In Section 9 of this form, we told you about possible other uses of your extra samples and information, outside 
this study. Please choose only one of the options below and write your initials or make your mark in the box next 
to it. Whatever you choose, the CoVPN will keep track of your decision about how your samples and information 
can be used. You can change your mind after signing this form.  
 
 
 
 I allow my extra samples and information to be used for other studies related to SARS -CoV -2 
prevention, the immune system, and other diseases.  
OR  
 I do not allow my extra samples to be used in any other studies.  
 
 
2. What does your signature [CONTACT_332680]?  
 
‚Ä¢ You understand the information given to you in this consent form.  
‚Ä¢ You accept the provisions in the form [ or, on behalf of the participant ]. 
‚Ä¢ You have had your questions answered and know that you can ask more.  
‚Ä¢ You agree to participate [ or permit the participant to join the study ]. 
 
You will not give up any of your [ or the participant‚Äôs ] legal rights by [CONTACT_50841].  
CONSENT TO TAKE PART IN THIS STUDY  
 
In consideration of all the above, I give my consent [ for my child/the participant ] to participate in this research 
study.  
 
Note to site: Next 3 lines are only for legally authorized representatives, parents, or guardians, giving consent for 
someone with cognitive incapacity or for a minor.  
 
LEGALLY AUTHORIZED REPRESENTATIVE (LAR)/PARENT/GUARDIAN INFORMED CONSENT  
 
 
___________________________  ___________________________  ___________  ____________  
LAR/parent/guardia n name (print)  LAR/parent/guardian  signature  [CONTACT_614656]: ____________________________  
 
 
 
CoVPN  5002 , Version 2.0  Page 41 of 48 
26 May 2021  ___________________________  ___________________________  ___________  ____________  
Participant‚Äôs name (print)  Participant‚Äôs signature [CONTACT_614657]  
 
 
 
___________________________  ___________________________  ___________  ____________  
Staff conducting consent  
discussion (print)  Staff signature  [CONTACT_614658], a witness should complete the signature [CONTACT_107019]:  
 
 
___________________________  ___________________________  ___________  ____________  
Witness‚Äôs name* (print)  Witness‚Äôs signature  [CONTACT_595052]  
 
*Witness is impartial and was present for the entire discussion of this consent form.  
CoVPN  5002 , Version 2.0  Page 42 of 48 
26 May 2021  APPENDIX III: SAMPLE ASSENT FORM  
 
CoVPN 5002  
 
 
SARS -COV -2 PREVALENCE STUDY  
 
Version 2.0  
26 May  2021  
DAIDS -ES ID: [ZIP_CODE]  
 
Sponsored by : [CONTACT_209060] (US) National Institute of Allergy and Infectious Diseases (NIAID), US National 
Institutes of Health (NIH)  
 
Site:  
Principal Investigator : 
[CONTACT_7626] : 
 
Population: Minors, ages 7 - 13 years, enrolling from community venues   
 
WHAT IS A RESEARCH STUDY?  
Research studies help us learn new things.  First, we ask a question.  Then we try to find the answer.   
 
This paper talks about our research and the choice that you have to take part in it.  We want you to ask us any 
questions that you have.  You can ask questions any time.  
 
IMPORTANT THINGS TO KNOW‚Ä¶  
‚Ä¢ You get to decide if you want to take part  
‚Ä¢ You can say ‚ÄòNo‚Äô or you can say ‚ÄòYes‚Äô  
‚Ä¢ No one will be upset if you say ‚ÄòNo‚Äô  
‚Ä¢ If you say ‚ÄòYes‚Äô, you can always say ‚ÄòNo‚Äô later  
‚Ä¢ You can say ‚ÄòNo‚Äô at any time  
 
WHY ARE WE D OING THIS RESEARCH?  
We are doing this research to find out how many people in your community have or have had the SARS -CoV -2 
coronavirus or COVID -19. 
 
WHAT WOULD HAPPEN IF I JOIN THIS RESEARCH?  
If you decide to be in the research, we would ask you to do th e following:  
‚Ä¢ Questionnaire: We would ask you some questions and mark your answers on our tablet. Your parent or 
guardian can help you answer those questions.   
‚Ä¢ Blood draws: We would collect a small amount of blood, about 2 teaspoons, with a needle.  
‚Ä¢ Nasal Swab ): We will use  a swab to collect some fluid from your nose.  
‚Ä¢ Saliva collection: You may be asked to provide some saliva . and an additional nasal swab. [Only 
include if your site is participating in this subset. Otherwise, delete.]  
 
COULD BAD THINGS HAPPEN IF I JOIN THIS RESEARCH?   
Drawing blood may cause some pain, bruise your arm, or make you a little dizzy. In rare cases you may faint. 
There is also a slight chance of infection after blood is drawn.  
CoVPN  [ADDRESS_815117] you 
like [include details of how staff will protect participants from exposure] . 
 
We will do everything we can to protect your privacy but there is a small chance that your information could be  
given to someone who should not have it. If that happened, you could face discrimination, stress, and 
embarrassment. We can tell you more about how your information will be protected, if you wish.  
 
 
COULD THE RESEARCH HELP ME?  
There may be no direct bene fits to participating in this study. However, being in the study might still help you in 
some ways. You will receive  the results of your  SARS -COV -[ADDRESS_815118] it or 
get it.  
 
This study may also help in the search for ways to prevent or treat COVID -19.  
 
WHAT ELSE SHOULD I KNOW ABOUT THIS RESEARCH?  
If you don‚Äôt want to be in the study, you don‚Äôt have to be.  
 
It is also OK to say yes and change your mind later.  You can stop being in the study at any time.  If you want to 
stop, please tell us.  
 
To thank you for being in the study, we would give you [$XX] . We will hand this money to your parent/guardian 
to hold for you.  
 
You can ask us questions any time.     
 
IS THERE ANYTHING ELSE?  
If you want to be in the study after we talk, please write your  name [CONTACT_50857].  We will write our name [CONTACT_614659].  This 
shows we talked about the research and that you want to take part.  
 
 
 
Printed Name [CONTACT_2385] _______________________________________________  
(To be written by [CONTACT_374419]/adolescent)  
CoVPN  5002 , Version 2.0  Page 44 of 48 
26 May 2021   
 
Signature [CONTACT_2385]  _______________________________________________  
(N/A for children who do not have a signature)  
 
 
Printed Name [CONTACT_236160] ___________________________________________________  
 
 
Signature [CONTACT_236160] _____________________________________________________ __ 
 
 
___________                                                              _____________  
Date                                                                     Time         
CoVPN  5002 , Version 2.0  Page 45 of 48 
26 May 2021  APPENDIX I V: SAMPLE VERBAL PRE -SCREENING SCRIPT  
 
CoVPN 5002  
 
SARS -COV -2 PREVALENCE STUDY  
 
Version 2.0  
  
26 May  2021  
DAIDS -ES ID: [ZIP_CODE]  
 
Sponsored by: [CONTACT_209060] (US) National Institute of Allergy and Infectious Diseases (NIAID), US National 
Institutes of Health (NIH)  
 
Site:  
Principal Investigator:  
[CONTACT_7626]:  
 
NOTE TO SITE: This script should be adapted to accommodate younger participants.  
 
  
 
Participant Information Sheet (to be summarized verbally or offered on paper  to all people who screen)  
 
Site [insert name [CONTACT_3816] ] 
Principal Investigator: [insert name ] 
Phone: [insert number ] 
 
Purpose: The purpose of this study is to estimate the number of people who have or have had SARS -COV -2 
virus in different communities in the [LOCATION_002].  
 
Commitment:  If you choose to join, you will have one study visit either right after signing this consent fo rm or at 
a later date at the clinic. If you are available now, the visit procedures will take place right here. You will 
complete a questionnaire, provide a blood  sample and have a nasal swab  collected.  Some participants may be 
asked  to also provide  a saliva samples  and additional nasal swab.  [Only include saliva if your site is participating 
in this subset. Otherwise, delete.]  [For participants recruited from health facilities, also include: We will also 
collect some information from your health records to document chronic diseases, smoking history, and history of 
SARS -CoV -2 diagnosis.]   
 
Benefits: There may be no direct benefit to you for taking part in this study, but the information learned from this 
study may help researchers develop new ways to prevent and/or treat SARS -CoV -2 infection. We will provide Interviewer Script:  
Hi, my name [CONTACT_832] [interviewer‚Äôs name] and I work at [name [CONTACT_3621]]. We are  
conducting a research study in this community and XX other communities in the  
[LOCATION_002] to estimate the number of people who have or have had the SARS -COV -
2 virus. Some people know this virus by [CONTACT_424948] ‚Äúcoronavirus.‚Äù It can cause the 
disease called COVID -19.  It can cause a disease called COVID -19. Please no te: You 
are a volunteer and can decide not  
to take part or can quit at any time.  
 
CoVPN  [ADDRESS_815119]: [insert name [CONTACT_114040]]  
 
The study will take place at: [insert site address]  
 
 
  
CoVPN  5002 , Version 2.0  Page 47 of 48 
26 May 2021  APPENDIX V: SUMMARY OF CURRENT SARS -COV -2 SURVEILLANCE STUDIES  
 
Study Title and Identifier  Study Description and Objective  Study Design  Location  
Surveillance of Individuals 
Following SARS -CoV -2 
Exposure ( [STUDY_ID_REMOVED] ) To better understand how long it takes an adult person to 
develop (or not develop) an infection with the SARS -
CoV -[ADDRESS_815120] with a person 
who has a confirmed infection.  Prospective longitudinal cohort 
study with 21 -day follow -up Bethesda, MD  
COVID -19: Human 
Epi[INVESTIGATOR_614626] -CoV -2 
(HEROS) ( [STUDY_ID_REMOVED] ) To: 1) determine the prevalence of SARS -CoV -2 carrier 
status over time in children and parents; 2) determine 
prevalence of antibody development over time in 
children and parents; 3) compare carrier status and 
antibody development for children with asthma and/or 
other atopic conditions versu s children without asthma 
and/or other atopic conditions; and 4) Investigate the 
presence of SARS -CoV -[ADDRESS_815121] COVID -19 
Occurrence and Severity 
([STUDY_ID_REMOVED] ) To better understand risk factors, symptoms, and 
treatments for COVID -[ADDRESS_815122] -to-participant, 
web-based, longitudinal study 
with 3 -month follow -up of adults  Outreach will target 
regions with high known 
prevalence of C OVID-
19 infection; however 
registration is open to all  
Seroprevalence of SARS -
CoV -2 Antibodies in 
Previously Undiagnosed 
Healthcare Workers 
([STUDY_ID_REMOVED] ) To identify healthcare workers with SARS -CoV -[ADDRESS_815123] not been previously diagnosed and 
are presumed COVID -19 negative, then determine the 
level of immunity in this population which could inform 
further decisions about widespread antibody testing in a 
healthcare worker population.  Cross -sectional  Mayo Clinic in 
Jacksonville, FL  
Longitudinal COVID -19 
Cohort Study 
([STUDY_ID_REMOVED] ) To assess whether survivors from severe COVID -19 
experience persistent functional impairments and to 
investigate the biologic mechanisms underlying these 
functional impairments.    Longitudinal study with 1 -year of 
follow -up of hospi[INVESTIGATOR_520162] -19 patient s University of Vermont 
and Johns Hopkins 
University  
CoVPN  5002 , Version 2.0  Page 48 of 48 
26 May 2021  Study Title and Identifier  Study Description and Objective  Study Design  Location  
SARS -CoV-2 Pandemic 
Serosurvey and Blood 
Sampling ([STUDY_ID_REMOVED])  To find the number of people with detectable antibodies 
to SARS -CoV-[ADDRESS_815124] no 
known exposure or clinical illness.  Cross -sectional  University of Alabama , 
National Institutes of 
Health Clinical Center , 
University of Pi[INVESTIGATOR_9109]  
 
 
 